Dr. Winston Tan

Hematology | Oncology
4500 San Pablo Rd S, 
Jacksonville, FL 
Offers Telehealth
4500 San Pablo Rd S, 
Jacksonville, FL 
OverviewInsuranceLocationsClinical Research

Overview

Winston Tan is a Hematologist and an Oncologist in Jacksonville, Florida. Dr. Tan is rated as an Experienced provider by MediFind in the treatment of Kienbock's Disease. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Urothelial Cancer, and Muscle Invasive Bladder Cancer.

His clinical research consists of co-authoring 15 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Mayo Clinic
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

MAYO CLINIC JACKSONVILLE
4500 San Pablo Rd S, Jacksonville, FL 32224

Additional Areas of Focus

Dr. Tan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Efficacy Trial of Pazopanib in Non-clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR
A Phase II Efficacy Trial of Pazopanib in Non-clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Drug
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 2
A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Enrollment Status: Completed
Publish Date: October 01, 2024
Intervention Type: Drug
Study Phase: Phase 1
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Pembrolizumab, Rituximab
Study Phase: Phase 1
Phase II Study Evaluating Combination Chemotherapy + Radiotherapy (RT) With Avelumab in Muscle Invasive Bladder Cancer
Phase II Study Evaluating Combination Chemotherapy + Radiotherapy (RT) With Avelumab in Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: January 06, 2023
Intervention Type: Other, Radiation, Drug
Study Drugs: Avelumab, Cisplatin, 5-Fluorouracil, Mitomycin C
Study Phase: Phase 2
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

15 Total Publications

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.
Journal: Journal for immunotherapy of cancer
Published: February 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tan's expertise for a condition
ConditionClose
    View All 75 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile